Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A SINGLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF ILV-095 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH PSORIASIS.

NCT01010542 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01010542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01010542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A SINGLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF ILV-095 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH PSORIASIS.
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
December 1, 2009
Completion date
May 20, 2011
Enrollment
39 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis